Alvotech and LOTTE Biologics sign US manufacturing partnership for multiple biosimilars
Alvotech and LOTTE Biologics have entered a US manufacturing agreement covering multiple antibody biosimilars for global supply.
LOTTE Biologics will manufacture drug substance at its 40,000-litre facility in Syracuse, New York, expanding Alvotech's production capacity and geographic manufacturing footprint.
The companies have also left scope to broaden the collaboration over time as Alvotech advances additional biosimilar programmes.
Field | Content |
Article Type | Deals |
Companies | Alvotech; LOTTE Biologics |
Deal Type | Long-term manufacturing partnership |
Programme Scope | Multiple antibody biosimilars |
Technology/Modality | Monoclonal antibody biosimilars |
Manufacturing Site | Syracuse, New York, United States |
Manufacturing Capacity | 40,000 litres |
Supply Scope | Global supply |
Manufacturing Responsibility | LOTTE Biologics will manufacture drug substance for selected Alvotech biosimilars |
What Happened | Alvotech and LOTTE Biologics signed a US-based manufacturing agreement covering multiple antibody biosimilars. |
Why It Matters | The agreement adds manufacturing capacity and geographic diversification to Alvotech's global biosimilar supply network. |
Strategic Rationale | Alvotech can broaden and de-risk production while LOTTE Biologics increases utilisation of its large-scale US biologics manufacturing infrastructure. |
Potential Impact | Additional US manufacturing capacity could support global supply resilience as Alvotech's biosimilar portfolio expands. |
Key Takeaway | LOTTE Biologics will manufacture multiple Alvotech antibody biosimilars at its 40,000-litre Syracuse facility. |
What to Watch | Identification of the covered biosimilars, timing of technology transfer and potential expansion of the partnership to additional programmes. |
Primary Source | Alvotech |
Relevant Date | 6 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare